RecruitingPhase 2NCT07137598
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Studying NON RARE IN EUROPE: Rheumatoid arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Afimkibart(drug)
- Enrollment
- 160 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (23)
- SunValley Arthritis Center Ltd., Peoria, Arizona, United States
- Inland Rheumatology Clinical Trials Incorporated, Upland, California, United States
- West Broward Rheumatology Associates, Inc., Tamarac, Florida, United States
- Willow Rheumatology and Wellness PLLC, Willowbrook, Illinois, United States
- Accurate Clinical Research Inc., Lake Charles, Louisiana, United States
- Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States
- Accurate Clinical Management, Houston, Texas, United States
- DM Clinical Research, Tomball, Texas, United States
- Rheumatic Disease Center, Glendale, Wisconsin, United States
- UZ Leuven, Leuven, Belgium
- Bispebjerg og Frederiksberg Hospital, Frederiksberg, Denmark
- CHU Strasbourg Hpital Hautepierre, Strasbourg, Bas Rhin, France
- Hopital de la Conception, Marseille, Bouches-du-Rhne, France
- Hopital Lapeyronie, Montpellier, Herault, France
- Hpital Cochin, Paris, Paris, France
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07137598 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Rheumatoid arthritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07200596The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy SubjectsGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2NCT07100938A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid ArthritisBeiGene
- RECRUITINGPHASE1NCT07040930Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.Changchun GeneScience Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07089381Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.Ain Shams University
- RECRUITINGNANCT06693479Could a Feedback Device Help Manage Work-related Shoulder Disorders?Laval University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06475495Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid ArthritisCharite University, Berlin, Germany
- RECRUITINGNCT07315997The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) StudyBrigham and Women's Hospital
- RECRUITINGNCT07463937A RWS of SC MTX in Chinese RA PatientsPeking University People's Hospital
See all trials for NON RARE IN EUROPE: Rheumatoid arthritis →